Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sodium phosphate drugs

This article was originally published in The Tan Sheet

Executive Summary

Rectal products containing sodium phosphate/sodium biphosphate would be required to bear sodium content and warning statements under a proposed rule published by FDA in the March 24 Federal Register. The proposal would apply the same requirements to rectal sodium phosphate drugs that now apply to other OTCs containing sodium. The action responds to concerns that individuals with certain medical conditions are at risk of an electrolyte imbalance when using such products. Comments are requested by June 22...

You may also be interested in...



For OTC And Supplement Success Stories, Firms Need Multiple Writers

Gaining market share in the increasingly competitive and regulated OTC and supplement sectors requires a collaborative approach with R&D, legal and marketing teams working together from the start, says Novartis Consumer executive Rosanne Rotondo.

For OTC And Supplement Success Stories, Firms Need Multiple Writers

Gaining market share in the increasingly competitive and regulated OTC and supplement sectors requires a collaborative approach with R&D, legal and marketing teams working together from the start, says Novartis Consumer executive Rosanne Rotondo.

For OTC And Supplement Success Stories, Firms Need Multiple Writers

Gaining market share in the increasingly competitive and regulated OTC and supplement sectors requires a collaborative approach with R&D, legal and marketing teams working together from the start, says Novartis Consumer executive Rosanne Rotondo.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel